EDUCATION EXHIBIT - Virtual Journal Club

Clinical Role of FDG PET in Evaluation of Cancer Patients

Published Online:https://doi.org/10.1148/rg.232025705

Positron emission tomography (PET) is a diagnostic imaging technique that allows identification of biochemical and physiologic alterations in tumors. Use of PET performed with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) significantly improves the accuracy of tumor imaging. In terms of oncologic applications, FDG PET has already gained widespread acceptance in the initial staging of cancer, management of recurrent cancer, and monitoring the response to therapy. With conventional imaging modalities, size criteria are used to distinguish between benign and malignant disease in lymph nodes; conversely, FDG PET is based on identification of fundamental aspects of tumor metabolism. FDG uptake in tumors is proportional to the metabolic rate of viable tumor cells, which have an increased demand for glucose. The high sensitivity and high negative predictive value of FDG PET in most malignant tumors enable this technique to play an even greater role in tumor management at initial staging and follow-up.

© RSNA, 2003

References

  • 1 McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 1995; 66:465-505.
  • 2 Wahl RL. Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” result. J Nucl Med 1996; 37:1038-1041.
  • 3 Kostakoglu L, Wong JCH, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 1996; 37:1771-1773.
  • 4 Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics 1999; 19:61-77.
  • 5 Abdel-Dayem HM, Rosen G, El-Zeftawy H, et al. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med 1999; 24:319-322.
  • 6 Leef JL, Klein JS. The solitary pulmonary nodule. Radiol Clin North Am 2002; 40:123-143.
  • 7 Lowe VJ, Duhaylongsod FG, Patz EF, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997; 202:435-439.
  • 8 Gould MK, MacLean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA 2001; 285:914-924.
  • 9 Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules. J Clin Oncol 1998; 16:1075-1084.
  • 10 Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705-713.
  • 11 Gdeedo A, Van SP, Corthouts B, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 1997; 10:1547-1551.
  • 12 Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202:441-446.
  • 13 Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001; 20:468-474; discussion 474–475.
  • 14 Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9:410-414.
  • 15 Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1581.
  • 16 Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42:1596-1604.
  • 17 Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42:1605-1613.
  • 18 Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32:1655-1660.
  • 19 Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996; 19:416-421.
  • 20 Patz EJ, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994; 191:379-382.
  • 21 Goldsmith SJ, Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am 2000; 38:511-524.
  • 22 Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-760.
  • 23 Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000; 7:85-87.
  • 24 Adson MA. Resection of liver metastases: when is it worthwhile? World J Surg 1987; 11:511-520.
  • 25 Philips RKS, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Local recurrence following curative surgery for large bowel cancer. II. The rectum and rectosigmoid. Br J Surg 1984; 71:17-20.
  • 26 August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984; 3:303-324.
  • 27 Moss AA. Imaging of colorectal carcinoma. Radiology 1989; 170:308-310.
  • 28 Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182:549-552.
  • 29 Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil NTS. J Clin Oncol 1996; 14:700-708.
  • 30 Guillem JG, Puig-La Calle J, Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43:18-24.
  • 31 Akhurst T, Larson S, Maccapinlac H, et al. Fluorodeoxyglucose (FDG) positron emission tomography (PET) immediately post-hepatic cryotherapy predicts recurrence of tumor in the liver (abstr). Proceedings of the annual meeting of the American Society of Clinical Oncology. Alexandria, Va: American Society of Clinical Oncology, 1999; 625.
  • 32 Krestin GP, Steinbrich W, Friedman G. Recurrent rectal cancer: diagnosis with MR imaging versus CT. Radiology 1988; 168:307-311.
  • 33 Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4:613-620.
  • 34 Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17:894-901.
  • 35 Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999; 86:932-937.
  • 36 Huebner RF, Park KC, Shepherd JE, Schwimmer J, Czernin J. A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
  • 37 Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
  • 38 Hustinx R, Paulus P, Daenen F, et al. Clinical value of positron emission tomography in the detection and staging of recurrent colorectal cancer. Gastroenterol Clin Biol 1999; 23:323-329.
  • 39 Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am Surg 1999; 65:1183-1185.
  • 40 Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with F18-fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703-707.
  • 41 Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503-511; discussion 511–513.
  • 42 Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997; 40:1195-1204.
  • 43 Cohen A, Minsky BD, Schilsky RL. Cancer of the colon. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia, Pa: Lippincott, 1997; 1144-1184.
  • 44 Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227:319-323.
  • 45 Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of F18-fluoro-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography. J Nucl Med 1992; 33:1972-1980.
  • 46 Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies for fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32:1485-1490.
  • 47 Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388-395.
  • 48 Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in lymphoma. Cancer 2002; 94:879-888.
  • 49 Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
  • 50 Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
  • 51 Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721-728.
  • 52 Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
  • 53 Mainolfi C, Maurea S, Varrella P, et al. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma: comparison with clinico-radiologic assessment. Radiol Med 1998; 95:98-104.
  • 54 Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999; 38:799-804.
  • 55 Thill R, Neuerburg J, Fabry U, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997; 36:234-239. [German].
  • 56 Kostakoglu L, Goldsmith SJ. [F-18] fluorodeoxyglucose positron emission tomography in staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27:1564- 1578.
  • 57 Munker R, Stengel A, Stabler A, et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin’s disease. Cancer 1995; 76:1460-1466.
  • 58 Bangerter M, Moog F, Griesshammer M, et al. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. Int J Hematol 1997; 66:517-520.
  • 59 Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996; 7:337-346.
  • 60 Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-3346.
  • 61 Moog F, Bangerter M, Kotzerke J, Guhlman A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-609.
  • 62 Surbone A, Longo DL, DeVita VT, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6:1832-1837.
  • 63 Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000; 214:253-257.
  • 64 Front D, Bar-Shalom R, Mor M, et al. Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999; 210:487-491.
  • 65 Cremerius U, Fabry U, Kroll U, et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma: results of a retrospective study in 72 patients. Nuklearmedizin 1999; 38:24-30. [German].
  • 66 Romer W, Hanauske A, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-4471.
  • 67 Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
  • 68 Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. Positron emission tomography predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018-1027.
  • 69 Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185-1189.
  • 70 Rankin SC. Oesophageal cancer. In: Husband JES, Reznek RH, eds. Imaging in oncology. Oxford, England: Isis Medical Media, 1998; 93-110.
  • 71 Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:417-424.
  • 72 Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53:659-665.
  • 73 Skehan SJ, Brown A, Thompson M, et al. Imaging features of primary and recurrent esophageal cancer at FDG PET. RadioGraphics 2000; 20:713-723.
  • 74 Brucher B, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response to therapy evaluation by positron emission tomography. Ann Surg 2001; 233:300-309.
  • 75 Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001; 71:290-294.
  • 76 Kelly S, Harris KM, Berry E, et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49:534-539.
  • 77 Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer 2000; 89:1019-1025.
  • 78 Minjnhout SG, Hoekstra OS, van Tulder MW, Teule GJJ, Deville WLJM. Systemic review of the diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91:1530-1542.
  • 79 Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17:1508-1515.
  • 80 Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19:2674-2678.
  • 81 Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4:396-402.
  • 82 Krug B, Dietlein M, Groth W, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma: diagnostic comparison with conventional imaging methods. Acta Radiol 2000; 41:446-452.
  • 83 Rinne D, Baum RP, Hor G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
  • 84 Holder WD, Jr, White RL, Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764-769.
  • 85 Hollenbeak CS, Lowe VJ, Stack BC. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 2001; 92:2341-2348.
  • 86 Davis JP, Maisey NM, Chevreton EB. Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery? J Laryngol Otol 1998; 112:125-127.
  • 87 Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255-1260.
  • 88 Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999; 125:1322-1328.
  • 89 Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26:112-115.
  • 90 Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol 1998; 19:1189-1196.
  • 91 Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200:135-141.
  • 92 Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997; 22:209-214.
  • 93 McGuirt WF, Greven KM, Keyes JW, Jr, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 1995; 104:274-278.
  • 94 Greven KM, Williams DW, 3rd, Keyes JW, Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 4:1355-1359.
  • 95 Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18:651-658.
  • 96 Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997; 19:666-674.
  • 97 McGuirt WF, Keyes JW, Jr, Greven KM, et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope 1995; 105:579-584.
  • 98 Wahl RL, Cody R, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770.
  • 99 Schiedhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23:618-623.
  • 100 Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: an accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220-227.
  • 101 Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39:4-8.
  • 102 Utech CI, Young CS, Winter PP. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23:1588-1593.
  • 103 Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
  • 104 Eubank WB, Mankoff DA, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19:3516-3523.
  • 105 Adler LP, Faulhaber PF, Schnur KC, et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203:323-327.
  • 106 Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14:1848-1857.
  • 107 Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001; 42:1198-1215.
  • 108 Noguchi M, Ohta N, Thomas M, et al. Risk of internal mammary lymph node metastases and its prognostic value in breast cancer patients. J Surg Oncol 1993; 52:26-30.
  • 109 Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000; 18:2817-2827.
  • 110 Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999; 210:807-814.
  • 111 Bender H, Kirst J, Palmedo H, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687-1692.
  • 112 Moon DP, Maddahi J, Silverman DHS, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431-435.
  • 113 Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88:2927-2933.
  • 114 Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13:1470-1477.
  • 115 Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-1695.
  • 116 Mallard J, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-1688.
  • 117 Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
  • 118 Charron M, Beyer T, Bohnen NN, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000; 25:905-910.

Article History

Published in print: Mar 2003